- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.
8 reports, 2 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 8
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA granted Fast Track Designation to Cidara's therapy CD388.1 source
Cidara submitted an End-of-Phase 2 meeting request to the FDA.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Cidara Therapeutics
company in San Diego, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireCidara Therapeutics to Participate in September Investor Conferences SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its propriet
- GlobeNewswireCidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics,
- GuruFocus.comCidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... Release Date: August 07, 2025 For the complete transcript of the earnings call, please refer to the full
- GlobeNewswireCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary
- GlobeNewswireCidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq
- Unknown outlet
- Unknown outlet
- Unknown outlet